Pfizer, Mylan Settle With Mass. AG Over EpiPen Commercial

Law360, New York (November 8, 2013, 3:22 PM EST) -- Pfizer Inc. and Mylan Specialty LP agreed to pay a combined $625,000 to Massachusetts for running a TV commercial touting allergic reaction treatment EpiPen that allegedly ran afoul of an existing consumer deception settlement, the state attorney general said Thursday.

Under separate agreements, EpiPen manufacturer Pfizer and exclusive licensee Mylan will pay $375,000 and $250,000 respectively to resolve claims that a 60-second ad that ran for a week in April 2012 misled consumers into believing that carrying the self-administered epinephrine injector alone was sufficient to protect against...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.